Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcutis Biotherapeutics (ARQT) Shares Issued (2020 - 2025)

Arcutis Biotherapeutics has reported Shares Issued over the past 6 years, most recently at -$1.3 million for Q4 2025.

  • Quarterly results put Shares Issued at -$1.3 million for Q4 2025, down 142.55% from a year ago — trailing twelve months through Sep 2025 was $4.4 million (up 0.84% YoY), and the annual figure for FY2024 was $1.7 million, up 45.79%.
  • Shares Issued for Q4 2025 was -$1.3 million at Arcutis Biotherapeutics, down from $1.3 million in the prior quarter.
  • Over the last five years, Shares Issued for ARQT hit a ceiling of $161.7 million in Q1 2024 and a floor of -$161.0 million in Q2 2024.
  • Median Shares Issued over the past 5 years was $360000.0 (2021), compared with a mean of $567777.8.
  • Biggest five-year swings in Shares Issued: soared 19275.0% in 2023 and later crashed 92647.7% in 2024.
  • Arcutis Biotherapeutics' Shares Issued stood at $167000.0 in 2021, then tumbled by 90.42% to $16000.0 in 2022, then soared by 19275.0% to $3.1 million in 2023, then changed by 0.0% to $3.1 million in 2024, then plummeted by 142.55% to -$1.3 million in 2025.
  • The last three reported values for Shares Issued were -$1.3 million (Q4 2025), $1.3 million (Q3 2025), and -$395000.0 (Q2 2025) per Business Quant data.